Antibacterial agent 332
Antibacterial agent 332 is an inhibitor of DsbA from Escherichia coli (EcDsbA). Antibacterial agent 332 reduces the swarming motility of Escherichia coli without affecting bacterial growth. Antibacterial agent 332 can be used in the research of bacterial infections caused by Escherichia coli.
For research use only. We do not sell to patients.
- CAS No.: 3106820-05-4
- Formula: C26H23F2N3O6
- Molecular Weight:511.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Antibacterial agent 332 (compound 17) (0-100 mM) binds to histidine-tagged E. coli DsbA, with a kinetic SPR KD of 2.2 μM and an equilibrium SPR KD of 2.8 μM[1].
Antibacterial agent 332 (50 μM; 180 s injection intervals) binds to Escherichia coli DsbA, with an ITC KD value of 1.5 μM determined based on the single-site binding model[1].
Antibacterial agent 332 inhibits Escherichia coli DsbA-mediated oxidation of native peptide substrates with an IC50 of 30 μM in peptide oxidation assays[1].
Antibacterial agent 332 (1 h, room temperature) shows a high enrichment rate in ASMS screening, indicating that it can form a stable complex with E. coli DsbA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3106820-05-4
-
Molecular Weight 511.47
-
Formula C26H23F2N3O6
-
SMILES
FC1=CC(C[C@@H](CO)NC(C#CC2=CC(NC(C3=NOC(C)=C3)=O)=CC=C2)=O)=CC(F)=C1CC(OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Aerobic Bacterial Batch Culture on Broth/Agar
Aerobic bacterial batch culture grows a closed inoculated population in broth or on agar without continuous medium replacement; growth readouts include turbidity/OD for total suspended biomass and colony-forming units for viable cells able to form colonies on agar. OD-based growth curves reflect light scattering by cells, but OD is instrument-, pathlength-, species-, cell-size-, and density-dependent, so OD should be calibrated or interpreted alongside viable counts when quantitative cell density is required.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)